Skip Nav Destination
Issues
1 November 2012
-
Cover Image
Cover Image
Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
Editorial
CCR Translations
CCR New Strategies
CCR Perspectives in Drug Approval
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
R. Angelo de Claro; Karen McGinn; Virginia Kwitkowski; Julie Bullock; Aakanksha Khandelwal; Bahru Habtemariam; Yanli Ouyang; Haleh Saber; Kyung Lee; Kallappa Koti; Mark Rothmann; Marjorie Shapiro; Francisco Borrego; Kathleen Clouse; Xiao Hong Chen; Janice Brown; Lara Akinsanya; Robert Kane; Edvardas Kaminskas; Ann Farrell; Richard Pazdur
Molecular Pathways
Review
Human Cancer Biology
Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas
Jana Slyskova; Vlasta Korenkova; Andrew R. Collins; Pavel Prochazka; Ludmila Vodickova; Jiri Svec; Ludmila Lipska; Miroslav Levy; Michaela Schneiderova; Vaclav Liska; Lubos Holubec; Rajiv Kumar; Pavel Soucek; Alessio Naccarati; Pavel Vodicka
Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells
Shahriar Koochekpour; Sunipa Majumdar; Gissou Azabdaftari; Kristopher Attwood; Ray Scioneaux; Dhatchayini Subramani; Charles Manhardt; Giovanni D. Lorusso; Stacey S. Willard; Hillary Thompson; Mojgan Shourideh; Katayoon Rezaei; Oliver Sartor; James L. Mohler; Robert L. Vessella
Cancer Therapy: Preclinical
Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A. Gilbert; Thiago da Silva; Ali Pedram; Ellis R. Levin; Isildinha M. Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A. Ince; Ji-Yeon Yang; Roel G.W. Verhaak; Yiling Lu; Gordon B. Mills; Joyce M. Slingerland
Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vivo Antitumor Activity
Seong-Hoon Yun; Eun-Seon Park; Sung-Won Shin; Yong-Woo Na; Jin-Yeong Han; Jin-Sook Jeong; Valeria V. Shastina; Valentin A. Stonik; Joo-In Park; Jong-Young Kwak
Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Seogkyoung Kong; Sadhak Sengupta; Betty Tyler; Anthony J. Bais; Qiangzhong Ma; Saryn Doucette; Jinyuan Zhou; Ayguen Sahin; Bob S. Carter; Henry Brem; Richard P. Junghans; Prakash Sampath
Imaging, Diagnosis, Prognosis
Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Dharanija Madhavan; Manuela Zucknick; Markus Wallwiener; Katarina Cuk; Caroline Modugno; Martina Scharpff; Sarah Schott; Jörg Heil; Andrey Turchinovich; Rongxi Yang; Axel Benner; Sabine Riethdorf; Andreas Trumpp; Christof Sohn; Klaus Pantel; Andreas Schneeweiss; Barbara Burwinkel
Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Masanori Terashima; Koji Kitada; Atsushi Ochiai; Wataru Ichikawa; Issei Kurahashi; Shinichi Sakuramoto; Hitoshi Katai; Takeshi Sano; Hiroshi Imamura; Mitsuru Sasako; for the ACTS-GC Group
Cancer Therapy: Clinical
A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Brigitte C. Widemann; AeRang Kim; Elizabeth Fox; Sylvain Baruchel; Peter C. Adamson; Ashish M. Ingle; Julia Glade Bender; Michael Burke; Brenda Weigel; Diana Stempak; Frank M. Balis; Susan M. Blaney
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q. Lee; Vinay K. Puduvalli; Joel M. Reid; John G. Kuhn; Kathleen R. Lamborn; Timothy F. Cloughesy; Susan M. Chang; Jan Drappatz; W. K. Alfred Yung; Mark R. Gilbert; H. Ian Robins; Frank S. Lieberman; Andrew B. Lassman; Renee M. McGovern; Jihong Xu; Serena Desideri; Xiabu Ye; Matthew M. Ames; Igor Espinoza-Delgado; Michael D. Prados; Patrick Y. Wen
Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin; Jessica Li; Jenny Wu; Rashell Kinard; Colin D. Weekes; Amita Patnaik; Patricia LoRusso; Rainer Brachmann; Raymond K. Tong; Yibing Yan; Ryan Watts; Shuang Bai; Priti S. Hegde
Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas; Christian Rothermundt; Dirk Klingbiel; Lukas Bubendorf; Rolf Jaggi; Daniel C. Betticher; Peter Brauchli; Denise Cotting; Cornelia Droege; Ralph Winterhalder; Daniele Siciliano; Dominik R. Berthold; Miklos Pless; Ralph Schiess; Roger von Moos; Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Yael P. Mossé; Emily Lipsitz; Elizabeth Fox; David T. Teachey; John M. Maris; Brenda Weigel; Peter C. Adamson; Mark A. Ingle; Charlotte H. Ahern; Susan M. Blaney
Predictive Biomarkers and Personalized Medicine
Letters to the Editor
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds